Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison

1

2

3 4 5 Ioanna-Evdokia Galani^{1,#}, Nikoletta Rovina^{2,#}, Vicky Lampropoulou¹, Vasiliki Triantafyllia¹, Maria Manioudaki¹, Eleftherios Pavlos¹, Evangelia Koukaki³, Paraskevi C. Fragkou⁴, Vasiliki Panou³, Vasiliki 6 7 Rapti⁴, Ourania Koltsida⁵, Andreas Mentis⁶, Nikolaos Koulouris³, Sotirios Tsiodras⁴, Antonia Koutsoukou² and Evangelos Andreakos^{1,7,*} 8 9 10 ¹ Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, 11 Biomedical Research Foundation of the Academy of Athens, Athens, Greece 12 ² ICU, 1st Department of Respiratory Medicine, National and Kapodistrian University of Athens, Medical School, 'Sotiria' General Hospital of Chest Diseases, Athens, Greece 13 14 ³ 1st Department of Respiratory Medicine, National and Kapodistrian University of Athens, Medical School, 'Sotiria' General Hospital of Chest Diseases, Athens, Greece 15 16 ⁴ 4th Department of Internal Medicine, Attikon University Hospital, University of Athens Medical School, 17 Athens, Greece ⁵ 2nd Respiratory Clinic, 'Sotiria' General Hospital of Chest Diseases, Athens, Greece 18 ⁶ Department of Microbiology, Hellenic Pasteur Institute, Athens, Greece 19 20 ⁷ Airway Disease Infection Section, National Heart and Lung Institute, Imperial College London, London 21 W2 1NY, United Kingdom 22 23 #These authors contributed equally to this work 24 25 * Corresponding author, e.mail: vandreakos@bioacademy.gr 26 Keywords: COVID-19, interferon, viral infection, hyperinflammation, cytokine storm 27 28 29 30 **Abstract**

- 31 A central paradigm of immunity is that interferon (IFN) mediated antiviral responses precede the pro-
- inflammatory ones, optimizing host protection and minimizing collateral damage^{1,2}. Here, we report 32
- 33 that for COVID-19 this does not apply. By investigating temporal IFN and inflammatory cytokine
- patterns in 32 COVID-19 patients hospitalized for pneumonia and longitudinally followed for the 34
- 35 development of respiratory failure and death, we reveal that IFN- λ and type I IFN production is both
- 36 diminished and delayed, induced only in a fraction of patients as they become critically ill. On the
- NOTIFIT PRINCIPAL TEMPORA TO A TRANSPORT OF THE PROPERTY OF TH 37

patients, and persist for a prolonged time. By comparison, in 16 flu patients hospitalized for pneumonia with similar clinicopathological characteristics to COVID-19 and 24 milder non-hospitalized flu patients IFN- λ and type I IFN are robustly induced, earlier, at higher levels and independently of disease severity, while pro-inflammatory cytokines are only acutely and transiently produced. Notably, higher IFN- λ levels in COVID-19 patients correlate with lower viral load in bronchial aspirates and faster viral clearance, and a higher IFN-λ:type I IFN ratio with improved outcome of critically ill patients. Moreover, altered cytokine patterns in COVID-19 patients correlate with longer hospitalization time and higher incidence of critical disease and mortality compared to flu. These data point to an untuned antiviral response in COVID-19 contributing to persistent viral presence, hyperinflammation and respiratory failure.

Main

38

39

40

41

42 43

44

45

46 47

48

49

50

51 52

53 54

55

56

57

58

59 60

61 62

63

64

65

66

67

68

69

70

71 72

73

74

75

76

77 78

79

Coronavirus Disease 2019 (COVID-19), triggered by the betacoronavirus SARS-CoV-2, has become one of the worst pandemics of our time, causing high incidence of pneumonia, acute respiratory distress syndrome (ARDS) and death^{3,4}. One of the most notable features of SARS-CoV2 infection is that it goes unnoticed for a remarkably prolonged period of time, running a course of a mild or uncomplicated illness for weeks until sudden and severe symptoms develop, in a subgroup of patients, requiring hospitalization, oxygen support and/or admission to an intensive care unit (ICU)^{3,4}. This is consistent with an unusually long incubation period of the virus, ranging from 2 to 14 days, and an unusually long presence of it in the respiratory tract, often being detectable for over a month after initial infection by conventional molecular diagnostic tests^{5,6}. By comparison, influenza virus infection, the main respiratory virus accounting for pneumonia hospitalizations till now, has an incubation time of 1 to 4 days, a short window of virus positivity of a few days, and an abrupt onset of symptoms causing pneumonia within 1-3 days^{7,8}. Other frequent respiratory viruses such as respiratory syncytial viruses, rhinoviruses, parainfluenza viruses, metapneumonoviruses and regular human coronaviruses have also shorter incubation times (ranging from 1-5 days) and more rapid and acute manifestation of symptoms⁹, rendering SARS-CoV2 quite unique in that respect. The basis of this is unknown but is likely to be a key driver of the pathophysiology of COVID-19 underlying its distinctive disease course and clinical manifestations.

The hallmark of COVID-19 is the development of a hyper-inflammatory response, also known as 'cytokine storm', impairing the gas-exchange function and leading to acute respiratory distress syndrome (ARDS), multi-organ failure and death¹⁰⁻¹². We and others have previously shown that a finely tuned antiviral response, orchestrated by IFN-λ (type III IFN) and type I IFN is critical for balancing immunity for optimal protection and minimal damage¹³⁻¹⁵. Deviation from this can unleash a detrimental 'cytokine storm' with devastating consequences for human health. A recent study suggested that in COVID-19 patients type I IFN and IFN- λ are not produced as they could not be detected in the sera of a small COVID-19 cohort of otherwise unspecified clinical characteristics¹⁶. In contrast, another one reported that type I IFN is induced in COVID-19 patients, and indicated that their levels might be reduced in those that are critically ill¹⁷. Such discrepancy could be due to the fact that each of these studies focuses on a single and likely distinct snapshot of an apparently heterogeneous disease process. Therefore, pursuing kinetic analyses is pertinent to delineating the course of the

80

81

82

83

84

85 86

87

88

89

90 91

92

93

94

95

96

97

98 99

100101

102

103

104

105

106

107108

109

110

111

112

113

114

115116

117

118119

120

121

immune response, especially given that cytokines are transiently produced. This is particularly true for IFNs which are expressed early during infection and are rapidly down-regulated thereafter. Here, we have performed a comprehensive temporal analysis of type I and type III IFN, and major inflammatory cytokine patterns in 32 COVID-19 and 16 influenza A virus infected (flu) patients hospitalized for community acquired pneumonia and longitudinally followed up according to current WHO guidelines¹⁸. Both groups of patients exhibited similar clinicopathological characteristics and comparable disease severity on admission (Table 1). We have also analyzed 24 milder flu patients with no radiological findings of pneumonia and no need for hospitalization (referred to as mild flu; Table 1), as well as 10 healthy individuals. Using high sensitivity Luminex and ELISA assays, we quantified 18 cytokines and chemokines relevant to antiviral immunity and hyperinflammation in patient sera collected at defined time intervals following hospital admission (Fig. 1a and S1aa). This aligns patients on the basis of the same clinical criteria of disease symptoms and severity, mainly the presence of pneumonia and the requirement for oxygen support. We found that COVID-19 patients had profoundly impaired induction of both IFN- λ and type I IFNs. Median levels of IFN- λ and type I IFNs were not detectable in most COVID-19 patients (Fig. 1b), although some patients made IFN- λ and fewer of them also IFN- α . This contrasts flu patients who almost uniformly expressed both types of IFNs, within the first (day 1-3) time interval of admission, and at significantly higher levels. At all cases, IFN expression was transient, with type I IFN levels rapidly declining after the first three days of hospitalization, while IFN- λ persisting longer. Interestingly, despite their limited ability to make IFNs, COVID-19 patients robustly expressed proinflammatory cytokines such as TNF, IL-6, IL-7, IL-8, IL-10, IFN-γ and CCL3 that were maintained at high levels for a prolonged time (Fig. 1b). Other cytokines such as IL-1\(\beta\), IL-12, IL-23 and CCL4 were also significantly up-regulated at specific time intervals compared to healthy individuals reflecting the heterogeneity of the disease course (Fig. S2). A similar pattern emerged when comparisons were made according to disease symptoms onset (Fig. S1b). COVID-19 patients exhibited markedly delayed and reduced IFN- λ and type I IFN levels which were detectable only in a fraction of the patients and from days 7-10 onwards of symptoms onset (Fig. S3, a-b). By comparison, all flu patients exhibited high levels during the first 6 days (Fig. S3, a-b). Although COVID-19 patients made little IFN during the first 6 days of symptom onset, they potently produced pro-inflammatory cytokines and chemokines such as TNF, IL-6, IL-8, IL-10 and CCL3 at levels similar to flu (Fig. S3, b-c). Moreover, they exhibited prolonged expression of pro-inflammatory mediators, with high levels of TNF, IL-6, IL-7, IL-8, IL-10 and CCL4 remaining detectable for over three weeks of onset, whereas in flu patients a number of these were by that time down-regulated (Fig. S3). Notably, COVID-19 patients were admitted to hospital with similar markers of systemic inflammation such as CRP levels, white blood cell (WBC) and neutrophil counts, and neutrophil/lymphocyte (N/L) ratio to flu patients (Table 1 and Fig. S4, a-f). They even had lower fever and a lower CURB-65 score, a commonly used measure of pneumonia severity¹⁹ (Fig. S4, g-h). However, during follow up COVID-19 patients developed a much higher incidence of ARDS requiring ICU support. In our cohort, 16 out of 32 patients (50%) developed critical disease, 3 of which died, compared to only 3 out of 16 flu patients (18.7%) none of which died (Fig. 2, a-b). Strikingly, COVID-19 patients became critically ill over a much broader time window (up to nine days after admission) than flu patients which manifested critical disease within the first day post admission. This is in agreement with the high incidence and protracted

122 course of severe respiratory failure described for COVID-19^{4,12}. Interestingly, among COVID-19 patients 123 those who became critically ill had higher CRP levels, WBC and neutrophil counts, and N/L ratio on 124 admission (Fig. S4, a-f), but not CURB-65 or fever (Fig. S4, g-h and Table S1). Critically ill flu patients 125 also had a tendency for higher WBC and neutrophil counts and a N/L ratio, as well as significantly 126 raised CURB-65, whereas non-hospitalized flu patients did not exhibit any of these increases (Fig S4, a-127 h). 128 We thus examined whether temporal cytokine patterns differ between the various patient groups. 129 Surprisingly, we observed that although COVID-19 patients that do not become critically ill produce 130 little type I or III IFN, the ones that become critically ill make IFN- λ which are significantly higher at the 131 day 1-3 time interval compared to healthy and non-critically ill patients (Fig. 2c and S5). Some of the 132 critically ill patients also make IFN-α (Fig. 2d and S5), albeit at significantly lower levels to mild non-133 hospitalized flu patients (Fig. 2d) or the total of hospitalized flu patients (both critically and noncritically ill; p<0.05). On the contrary, all COVID-19 patients make pro-inflammatory cytokines such as 134 135 TNF, IL-6, IL-8, IL-10 and IFN-γ, with critically ill patients exhibiting also higher levels of IL-6, IL-7 and 136 TNF at specific time intervals, and a tendency for higher IFN-γ consistent with the increased hyper-137 inflammatory state they are in (Fig. 2e, S5 and S6). Individual patient data further confirmed these trends (Fig. S7). Interestingly, CCL3 is significantly higher than healthy controls in non-critically ill 138 139 COVID-19 patients but not in the critically ill ones (Fig. S6). By comparison, critically ill and non-140 critically ill flu patients did not differ in their ability to make type I and type III IFNs nor pro-141 inflammatory cytokines such as TNF, IL-6 or IL-7 (Fig. 2, c-e, S5 and S6). Similarly, non-hospitalized flu patients with mild disease exhibited strong production of type I and type III IFNs, indicating that across 142 143 the spectrum of flu disease severity the antiviral response remains robust. Visualizing these patterns 144 on radar plot reveals a major imbalance in the induction of antiviral and pro-inflammatory responses 145 of COVID-19 patients that does not occur in flu (Fig. 2e).

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

We next sought to determine whether imbalanced cytokine patterns in COVID-19 patients are related to systemic immune effects, and parameters linked to disease severity. To that end, we obtained temporal white blood cell transcriptomes from 5 healthy individuals and 9 COVID-19 patients, 5 noncritically and 4 critically ill, starting from day 1 of entry to the ward or ICU and at different timepoints thereafter. In total, 24 comprehensive RNAseq gene expression datasets were analyzed, clustering according to the clinical phenotype and indicating this as the main source of variation (Fig. 3a and S8a). Focusing at day 1 as the most relevant timepoint, we found that 4225 genes were differentially expressed (DEGs) in COVID-19 patients compared to healthy individuals (Table S2). When critically and non-critically ill patients were compared separately to healthy controls, 4225 and 4902 DEGs were observed, respectively, of which 1979 were common whereas the rest were uniquely found in one or the other patient group (Fig. S8b, Table S2 and Table S3). Volcano plots pointed out notable differences in the most highly regulated genes between the groups with critically ill patients exhibiting a stronger immune and antiviral response gene patterns (Fig. S8, c-e). Pathway analysis of DEGs indeed revealed that the most significant pathways over-represented in critically ill patients were related to the positive regulation of the immune system, the activation of the innate immune response, the defense response to virus and the cellular response to IFN (Fig. 3b and Table S4). By contrast, in noncritically ill patients these pathways were not significant; the ones over-represented instead included the regulation of the cellular component size, IL-1 β production and NK cell cytotoxicity (Fig. 3b).

165

166

167

168 169

170 171

172

173

174

175

176 177

178

179

180

181

182

183

184

185

186 187

188

189 190

191

192

193

194 195

196

197

198

199

200 201

202

203

204

205

206

Accordingly, heatmaps with temporal information unveiled the systemic activation of the innate immune response marked by the up-regulation of key pro-inflammatory genes and pattern recognition receptors (C4bpa, Csf1, Il1rn, Cxcl10, Mmp8, Stat1, Ddx58/Riqi, Tlr4, Nlrp6), and the induction of a dominant activated neutrophil-myeloid cell signature (Mpo, Elane, Cd177, Itgam, Arq1, Ceacam8, Fcqr1a) in the critically ill group that was milder and not significant in non-critically ill patients (Fig. 3, c-d). On the contrary, T and B lymphocyte lineage and related genes (Cd3d, Cd3e, Cd4, Cd8a, Cd19, Cd22) were markedly down-regulated in critically ill patients. These data are consistent with lymphopenia, high neutrophil counts, and a high N/L ratio also present in these patients (Fig. S4) and previously reported to be associated with more severe disease and worse outcomes in COVID-19 patients^{3,4}. Cytokines such as TNF, IL-6 and IL-8 may directly account for these effects, as they are well known to trigger the mobilization and activation of neutrophils, the development of lymphopenia and the induction of innate immune responses and systemic inflammation^{20,21}. Notably, a long set of IFNstimulated genes (ISGs) was also strongly induced in critically ill patients compared to only a fraction of them being up-regulated in the non-critically ill group (Fig 3e and S8f), in agreement with the patterns of IFN- λ and type I IFN production in these patients. This cannot be attributed to differential expression of IFN receptors as no differences between IfnIr1, II10rb, Ifnar1 and Ifnar2 mRNA levels were observed among patient groups and healthy individuals with the exception of a 2-fold upregulation of the already high levels of Ifnar2 in critically ill patients (Table S2). Interestingly, imbalanced cytokine patterns in COVID-19 patients with pneumonia were associated with a much worse disease outcome compared to flu. First, the COVID-19 group exhibited higher incidence of critical disease and mortality (Fig. 2b). Second, COVID-19 patients overall, as well as when grouped as critically and non-critically ill, required longer hospitalization time than their flu counterparts (Fig. 4, a-c). For non-critically and critically ill COVID-19 patients, median time was 14 and 23 days, respectively, compared to flu that was 7 and 19 days (Fig. 4, b-c). Prolonged hospitalization could be attributed to the untuned antiviral responses, leading to a more protracted clinical course of COVID-19 relative to flu and a need for longer recovery even for the non-critically ill group. To identify cytokines and cytokine combinations that can predict hospitalization time and therefore be of prognostic value, we generated a correlation matrix of the cytokine levels at admission (days 1-3 interval) and the duration of hospital stay (Fig. 4d). We found that higher IL-6 and IL-10, and lower CCL3 levels, are directly proportional to the duration of hospitalization (Fig. 4, d-f). The value of TNF and IL-6 as biomarkers for monitoring COVID-19 severity has been reported^{4,22,23} but for CCL3 this is new. Interestingly, IFN- λ levels also correlated with higher IL-6, and longer hospitalization, consistent with their almost exclusive induction in critically but not non-critically ill patients (Fig. 4d and 2c). A question that arises is whether IFN levels induced in critically ill patients are beneficial as delayed type I or type III IFN production has been shown in animal models to cause immunopathology^{13,14,24} or interfere with epithelial repair^{25,26}, respectively. We found that higher IFN- λ concentrations during ICU entry were associated with lower SARS-CoV2 viral load in the respiratory tract and faster viral clearance (Fig. 4, g-h). Moreover, a higher IFN- λ to type I IFN ratio at that time was linked to a shorter stay in the ICU (Fig. 4i), with the two patients with the highest IFN- α levels also exhibiting the longest stay (both 23 days over a median of 17 days). These data suggest that delayed IFN- λ induction may still be protective in critically ill COVID-19 patients whereas IFN- α may do more harm than good, at least in a subset of patients.

Taken together, our findings demonstrate that SARS-CoV2 infection does not follow the conventional paradigm of antiviral immunity. Instead of activating first the antiviral response followed by the proinflammatory process as a second line of protection, it does the opposite; it triggers the proinflammatory response long before IFN-mediated antiviral defenses are induced- if at all. This is a major paradox and helps explain many of the unique or unusual features of COVID-19. The long virus incubation time and persistence in the respiratory tract, giving positive SARS-CoV2 tests for weeks, can be attributed to the delayed and/or reduced production of type I and III IFNs. The absent or very mild symptoms of patients for an unusually extended period of time, can be attributed to the lack or impaired and delayed expression of type I IFNs, principal mediators of flu-like disease and symptoms such as runny nose, coughing, fatigue, dyspnea and fever in humans²⁷. Finally, the early and persistent expression of pro-inflammatory cytokines culminating into prolonged hyper-inflammation can promote the sudden development of respiratory failure requiring hospitalization and frequently ICU admission. Noteworthy, in flu the swift induction of the type I and III IFN response, across the spectrum of disease severity, correlates with quicker recovery, and markedly lower incidence of critical disease or mortality^{13,24}. The recent demonstration in a retrospective cohort study of 446 COVID-19 patients that early administration of IFN- α (interferon-a2b) is linked to reduced in-hospital mortality whereas late IFN- α therapy leads to increased mortality and delayed recovery leaves little doubt that the timing of IFN production is also crucial in COVID-19 patients²⁸. Conceivably, late production of type I or III IFN production might confer no viral resistance, but instead promote immunopathology. Whether this unique clinical course of COVID-19 is related to the presence of SARS-CoV2-derived IFN inhibitors as previously proposed for SARS-CoV^{29,30} and MERS-CoV³¹ is not known but is a possibility. As with other viruses, inhibition may be overcome once higher viral loads are reached, e.g. after incubation of the virus and eventual spread in susceptible individuals. In our study, we did not see significant differences in virus levels between non-critically and critically ill patients at the time IFNs were measured (Fig. S9). However, higher virus load in severe over mild disease has been described in one study but not been confirmed in another^{32,33}. Moreover, higher virus load can overcome SARS-CoV2 dose-dependent suppression of IFN production in cultured respiratory epithelial cells¹⁶. Our study is not without caveats. First, it characterizes cytokine patterns in the circulation, and although these are commonly used to analyze 'cytokine storms' in response to infection, how well they correlate to immune responses in the respiratory tract is difficult to know. Second, it is relatively small, and our findings await validation in other cohorts. Still, our study is uniquely informative as it addresses the production of IFNs and the activation of the 'cytokine storm' in COVID-19 in a temporal manner, from hospital admission to ICU entry, and should therefore be particularly useful for the design of clinical trials testing IFN therapies. Finally, it provides a side-by-side comparison of COVID-19 with flu, studying patient populations with similar genetic, demographic and clinicopathological

Methods

207

208

209

210

211

212213

214

215

216

217218

219

220

221222

223

224225

226

227228

229

230

231

232233

234

235

236

237

238

239

240

241

242

243

244

245

246247

248

249

Study participants

In this non-interventional study thirty two patients with diagnosis of COVID-19 pneumonia according to WHO guidelines and positive SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR)

characteristics, and therefore uncovers important differences in the antiviral immune response

between these two diseases that have not been previously suspected.

- testing on a respiratory sample (nasopharyngeal swab or bronchial aspirate) were included¹⁸. Patients
- were recruited between March and April 2020 from the 1st Respiratory and Critical Care Clinic ward and
- 252 ICU of the "Sotiria" General Chest Diseases Hospitalof Athens, Greece. Healthy, asymptomatic subjects
- with a negative SARS-CoV-2 RT-PCR at the time of inclusion served as the control group.
- The severity of COVID-19 cases was classified based on the adaptation of the Seventh Revised Trial
- Version of the Novel Coronavirus Pneumonia Diagnosis and Treatment Guidance³⁴. All patients had
- 256 moderate to severe disease, and presented with respiratory symptoms and radiological findings of
- pneumonia. They met any of the following criteria:
- 258 1. Respiratory distress (≥30 breaths/ min);
- 259 2. Oxygen saturation ≤93% at rest;
- 3. Arterial partial pressure of oxygen (PaO2)/ fraction of inspired oxygen (FiO2) ≤300mmHg with no
- other organ failure.
- 262 Sixteen patients developed ARDS and critical illness due to respiratory failure (PaO2/FiO2 ≤ 200
- 263 mmHg) requiring mechanical ventilation, with shock and/or other organ failure necessitating intensive
- 264 care unit (ICU) care.
- 265 Blood was drawn at various time intervals during hospitalization and at discharge; and white blood
- 266 cells and plasma were collected and stored. Serum was also stored, almost daily, for further use.
- 267 In order to better understand the immune response of COVID-19 infection, subjects from a cohort of
- patients with confirmed H1N1/H3N2 influenza A virus (flu) infection were also studied. In total, 40
- 269 patients were recruited at the 2nd Respiratory Clinic of the 'Sotiria' General Chest Diseases Hospital,
- 270 Athens, Greece and the "Attikon" University Hospital, University of Athens Medical School, Athens,
- 271 Greece. Confirmation was obtained from nasopharyngeal swabs using the BioFire
- 272 FilmArray Respiratory Panel test (bioMerieux). Patients were categorized according to the severity of
- the disease into mild flu patients with no radiological findings of pneumonia, no need for oxygen
- 274 support and hospitalization, and moderate to severe flu patients with radiological findings of
- 275 pneumonia (x-ray or CT), oxygen need and symptoms requiring hospitalization. Hospitalized flu
- patients could be subdivided into patients that did not develop (PaO2/FiO2 > 200 mmHg) or developed
- 277 critical disease (PaO2/FiO2 ≤ 200 mmHg). Flu patients had similar clinico-pathological characteristics to
- 278 COVID-19 patients upon admission (Table 1). All subjects included in the study were clinically
- 279 evaluated and followed longitudinally during the whole period of hospitalization (from admission to
- 280 discharge). All blood specimens were processed immediately for serum collection and aliquots were
- 281 stored at -80°C.

286 287

291

- The study conforms to the principles outlined in the Declaration of Helsinki, and received approval by
- 283 the Ethics Committees of the "Sotiria" General Chest Diseases Hospital, Athens, Greece (Approval
- numbers 16707/10-7-18 and 8385/31-3-20) and the "Attikon" University Hospital, University of Athens
- 285 Medical School, Athens, Greece (Approval number 1821A/22-9-16).

SARS-CoV-2 detection

- 288 RNA was extracted from nasopharyngeal swabs and bronchial aspirates by using the Nuclisens easyMAG
- instrument (bioMerieux), according to the manufacturer's instructions. Real time RT-PCR was performed
- on extracted nucleic acids targeting the E gene of SARS-CoV-2 as described by Corman et al³⁵.

292 Cytokine analysis

- Serum samples frozen and stored at -20° C, without other thawing, were analyzed for the presence of
- 294 IFNγ, TNF, IL-1β, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13, IL-17A, IL-23, CCL3, CCL4 and CX3CL1

with the MILLIPLEX MAP Human High Sensitivity T cell Panel (Merck Millipore). Thawed serum aliquots were centrifuged at 13,000 rpm for 10 min at 4°C immediately prior to testing. Each assay was performed according to the manufacturer's protocol for serum samples, utilizing recommended sample dilutions and standard curve concentrations (Merck Millipore). Samples were analyzed on a Luminex 200^{TM} System according to the manufacturer's instructions (Merck Millipore). For each cytokine on each assay, the lowest detection limits were in pg/ml: 0.50 for IFN- γ , 0.42 for TNF, 0.2 for IL-1 β , 0.24 for IL-2, 0.60 for IL-4, 0.16 for IL-6, 0.33 for IL-7, 0.30 for IL-8, 0.50 for IL-10, 0.24 for IL-12 (p70), 0.20 for IL-13, 0.50 for IL-17A, 8.00 for IL-23, 2.00 for CCL3, 0.80 for CCL4 and 10.00 for CX3CL1. High sensitivity sandwich Enzyme-linked Immunosorbent Assay (ELISA) kits were used for the detection of human IFN- α (Thermo Scientific) and IFN- λ 1 (Biolegend). Their sensitivity in pg/ml was 1.00 for IFN- α and 2.00 for IFN- λ 1.

RNAseg analysis

For RNAseq analysis, total RNA was purified from whole blood leukocytes with the RNeasy Micro kit (Qiagen). RNA samples were treated with DNase I (Qiagen) and quantified on a NanoDrop (Thermo Scientific). NGS libraries were prepared with the TruSeq RNA Library Prep Kit v2 (Illumina) according to the manufacturer's instructions. Quality of the libraries was validated with an Agilent DNA 1000 kit run on an Agilent 2100 Bioanalyzer. Library samples were quantified using a Qubit™ dsDNA HS Assay Kit (Thermo Scientific) according to the manufacturer's instructions. Bar-coded cDNA libraries were pooled together in equal concentrations in one pool, and were sequenced on a NextSeq 500 System (Illumina) at the Greek Genome Center (Biomedical Research Foundation, Academy of Athens, Athens, Greece).

Transcriptomics analyses

Samples sequenced on NextSeq 500 (Illumina) were analyzed using standard protocols. Briefly, raw reads were pre-processed using FastQC v.0.11.2 and cutadapt v.1.6, and then mapped to the human genome (GRCh38) using the TopHat version 2.0.13, Bowtie v.1.1.1 and Samtools version v.1.1. The read count table was produced using HTSeq v.0.6. Following filtering of raw read counts with a threshold of 10 in at least one dataset, resulting in a total of 21880 genes, DESeq2 analysis was performed ³⁶. This returned the log2foldchanges of the treatment compared to healthy individuals for each time point. Differentially expressed gene transcripts were selected based on an adjusted *p*-value cutoff of 0.05 (FDR 5%). Pathway enrichment analysis was conducted using ClueGO and CluePedia plugin of Cytoscape. Heatmaps were performed using TM4 MeV v.4.8 and Euclidean distance was used for hierarchical clustering. Clustering and dendrograms were performed with hclust function and ggdendro package, respectively, in R.

Data and software availability

The raw RNAseq data have been deposited at GEO (http://www.ncbi.nlm.nih.gov/geo/) under BioProject accession number # PRJNA638753.

Statistical analysis

Data were analyzed on GraphPad Prism software. Statistical significance of differences was assessed using the Mann-Whitney U (MWW) test for non-parametric data. Associations between cytokines and hospitalization time (in days) were tested using Spearman rank-order correlation coefficient and

visualized using the corrplot R package. Polar charts from the ggplot2 R package were used for the visualization of the differences in cytokine response patterns.

Acknowledgements

338

339

340

341

342

343

344 345

346

347

348

349

350

351

352

353

354

355

The authors would like to thank Dr A. Gavriil and G. Vatsellas for technical assistance, and Prof. P. Katsikis and V. Soumelis for critically reading the manuscript. EA is supported by research grants from the European Commission (IMMUNAID, No 779295 and CURE, No. 767015), the Hellenic Foundation for Research and Innovation (INTERFLU, No 1574) and Janssen Pharmaceuticals. IEG is supported by a research grant from the Hellenic Foundation for Research and Innovation (RELIEVE, No 506). This work received also a donation from the J. Sanchez family and friends.

Conflict of interest

The authors declare that they have no conflict of interest.

Tables

Table 1. Clinical, laboratory and imaging findings of the study patients on hospital admission

Characteristics	COVID-19 Patients Moderate-to-severe, hospitalized (N=32)	FLU Patients	
		Moderate-to-severe,	Mild, non-
		hospitalized (N=16)	hospitalized (N=24#)
Age			
Median (IQR), yr	63 (49-77)	62.5 (52-73)	46 (31-50)
Age ≥65 yrs, no (%)	13 (41)	8 (50)	2 (8)
Male, no (%)	22 (69)	9 (56)	13 (54)
Smoking history, no (%)			
Never smoked	22 (69)	7 (44)	8 (40) (N=20)
Former smoker	4 (12)	3 (19)	1 (5) (N=20)
Current smoker	7 (22)	6 (37)	11 (55) (N=20)
Coexisting disorder, no			
(%)			
Any	19 (59)	13 (81)	10 (50) (N=20)
Diabetes	7 (22)	2 (12.5)	0 (0) (N=20)
Hypertension	12 (37.5)	8 (50)	2 (10) (N=20)
Cardiovascular disease	2 (6)	2 (12.5)	1 (5) (N=20)
COPD	0	6 (37.5)	2 (10) (N=20)
Asthma	3 (9)	1 (6)	0 (0) (N=20)
Cancer/Hematological malignancy	0 (0)/0 (0)	1 (6)/0 (0)	0 (0)/ 0 (0) (N=20)
Chronic renal disease	0 (0)	0 (0)	0 (0)
Overweight/Obese	17 (53)/8 (25)	N/A /2 (12.5)	N/A/ 0 (0)

		T	
Median interval from first			
symptoms on admission	5 (2-7)	1 (1-2.5)	2 (1-2) (N=16)
(IQR), days			
Fever on admission			
Patients, no/Total no (%)	12 (37.5)	16 (100)	19 (100) (N=19)
Median temperature	37.5 (36.5-38.1)	38.5 (38.4-39)	38.6 (38.2-39)
(IQR), °C	37.3 (30.3 30.1)	30.3 (30.4 33)	30.0 (30.2 33)
Symptoms on admission,			
no (%)			
Dyspnea	21 (66)	N/A	N/A
Cough	20 (62)	11 (69)	8 (40) (N=20)
Fatigue	18 (56)	12 (75)	20 (100) (N=20)
Myalgia	4 (12)	8 (50)	13 (65) (N=20)
Diarrhea/ vomiting	6 (19)	4 (25)	4 (20) (N=20)
Median oxygen	3 (2-6)	9.5 (6-11)	0
requirement (IQR, L/min)	3 (2-0)		
CURB-65 score (IQR)	1 (0-2)	3 (1-3)	0
Laboratory findings on			
admission			
Leukocytes (IQR) x 10 ⁹ /L	6.40 (4.61-8.52)	7.27 (5.96-8.55)	5.85 (4.26-7.39) (N=16)
Neutrophils (IQR) x 10 ⁹ /L	5.65 (3.32-7.45)	5.08 (3.66-7.42)	4.26 (2.48-5.13) (N=16)
Lymphocytes (IQR) x 10 ⁹ /L	0.95 (0.54-1.37)	0.77 (0.59-1.48)	1.07 (0.72-1.42) (N=16)
Monocytes (IQR) x 10 ⁹ /L	0.40 (0.28-0.57)	N/A	N/A
Platelets (IQR) x 10 ⁹ /L	190 (131-242)	203 (180-242)	200 (164-227) (N=16)
CRP mg/dl, (IQR)	13.6 (3.64-19.4)	5.5 (1.65-12.6)	1.33 (0.82-2.40) (N=16)
Lactate dehydrogenase	224 (202 455)	300 (244-320)	215 (200-250) (N=16)
(LDH) (IQR), IU/L	334 (203-455)		
Alanine aminotransferase	29 (23-39)	27 (20-48)	16 (12-22.5) (N=16)
(ALT) >40 IU/L			
Ferritin (IQR), ng/ml	677 (395-1237)	N/A	N/A
PCT (IQR), ng/ml	0.08 (0.04 - 0.38)	N/A	0.06 (0.06-0.08) (N=10)
Chest X-ray findings on			
admission			
Abnormal results, no (%)	30 (94)##	15 (94)##	0 (0)
Unilateral infiltrates	4 (12.5)	5 (31)	0 (0)
Bilateral infiltrates	26 (81)	10 (63)	0 (0)

³⁵⁶ #In some cases, data available for fewer patients as indicated.

N/A: Not available

358

359

360

361

362 363

364

365

366

Figure legends

Fig. 1: Temporal IFN and inflammatory cytokine patterns of COVID-19 and flu patients in relation to hospital admission. a, Schematic showing the experimental design with sampling at specific time intervals after hospital admission of 32 COVID-19 and 16 flu patients with pneumonia. b, Levels of IFN- λ 1, IFN- α , IFN- γ , TNF, IL-6, IL-7, IL-8, IL-10 and CCL3 at various time intervals after hospital admission. Data are presented as scatter plots with dots showing individual patient measurements and columns median values with range. For COVID-19, n=16, 17, 21, 15, 11 and 8 for each of the six consecutive

³⁵⁷ ## X-ray negative patients were positive for unilateral or bilateral opacities on CT.

time intervals. For flu, n=16, 14 and 11, respectively. For healthy, n=10. Grey shading marks the limit of quantification of the assay. P values were determined by a two tailed Mann–Whitney U test for non-parametric comparisons. *P < 0.05, **P < 0.01 and ***P < 0.001 show significance over healthy controls. *P < 0.05, **P < 0.01 and ***P < 0.001 show significance between COVID-19 and flu groups.

Fig. 2: Comparison of IFN and inflammatory cytokine patterns between subgroups of COVID-19 and flu patients according to disease severity. a, Schematic depicting the longitudinal follow up of 32 COVID-19 and 16 flu patients hospitalized for pneumonia, and 24 non-hospitalized (N.H.) flu patients with no radiological findings of pneumonia. b, Incidence of critical disease in hospitalized COVID-19 and flu patients over time. **c-d**, Levels of IFN- $\lambda 1$ (c) and IFN- α (d) of critically and non-critically ill patients, and mild non-hospitalized patients at day 1-3 and 7-10 time intervals after hospital admission or visit, respectively, as well as healthy individuals. Dots show individual patient measurements and lines median values of hospitalized patients and healthy individuals. Squares show non-hospitalized flu patients. Grey shading marks the limit of quantification of the assay. e, Radar plots of median cytokine levels and range of hospitalized COVID-19 and flu patients developing critical versus non-critical illness, non-hospitalized flu patients and healthy individuals at the day 1-3 time interval after admission. Each circle in the radar plot represents logarithmically increasing concentrations from 4 to 256 pg/ml as shown in the healthy control. For days 1-3 n=9, 7, 24, 13 and 3 for each of the five consecutive groups, respectively. For days 7-10 n=8, 13, 15, 12 and 2, respectively. For healthy individuals, n=10. P values were determined by a two tailed Mann–Whitney U test for non-parametric comparisons. *P < 0.05, **P < 0.01 and ***P < 0.001 show significance over healthy controls. $^{\#}P$ < 0.05, $^{\#\#}P$ < 0.01 and $^{\#\#}P$ < 0.001 show significance between COVID-19 and flu subgroups.

Fig. 3: Kinetic analysis of blood transcriptional signatures of critically and non-critically ill COVID-19 patients. a, Principal component analysis of peripheral white blood cell transcriptomes of critically ill (n=4) and non-critically ill (n=5) patients or healthy (H1-H5) controls (n=5). **b,** Gene ontology (GO) pathway enrichment analysis of differentially expressed genes of all, critically ill and non-critically ill patients at day 1 of hospital or ICU entry. **c-e,** Heatmaps of differentially expressed innate immunity, leukocyte and IFN-stimulated genes and their kinetics following hospitalization of critically ill and non-critically ill COVID-19 patients compared to healthy controls. Data are expressed as log2 fold values over healthy controls.

Fig. 4: Correlation of IFN and cytokine expression patterns with disease outcomes. a-c, Comparison of hospitalization time between COVID-19 and flu patients. All patients (a), patients with non-critical disease (b) and patients with critical disease (c) are shown. d, Correlation matrix of cytokine concentration levels at the day 1-3 time interval after hospital admission of COVID-19 patients indicating correlations between cytokines and total hospitalization time (TIME) or other cytokines. e-f, Correlation of IL-6 (e) and CCL3 (f) concentration levels with the duration of total hospitalization of all COVID-19 patients. g, Correlation of IFN- λ 1 concentration levels with viral load expressed as CT values in bronchial aspirates collected at the same time interval as the sera used for IFN- λ 1 quantification. h, Correlation of IFN- λ 1 concentration levels with time required for viral clearance assessed as the first –

- 408 ve SARS-CoV2 test. **i**, Correlation of IFN- λ 1:IFN-α ratio with the duration of hospitalization in the ICU.
- 409 Dots show individual COVID-19 patient measurements and shaded dot plots values corresponding to
- 410 COVID-19 patients becoming critically ill. P values were determined using the Spearman rank-order
- 411 correlation coefficient for non-parametric data. *P < 0.05, **P < 0.01 and ***P < 0.001

References

412

413

414

- 415 1. Sen, G.C. Viruses and interferons. *Annu Rev Microbiol* **55**, 255-281 (2001).
- 416 2. McNab, F., Mayer-Barber, K., Sher, A., Wack, A. & O'Garra, A. Type I interferons in infectious disease. *Nat Rev Immunol* **15**, 87-103 (2015).
- 418 3. Guan, W.J., et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 419 382, 1708-1720 (2020).
- 420 4. Huang, C., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, 421 China. Lancet **395**, 497-506 (2020).
- Wolfel, R., et al. Virological assessment of hospitalized patients with COVID-2019. *Nature* (2020).
- 424 6. Zheng, S., et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 425 in Zhejiang province, China, January-March 2020: retrospective cohort study. *BMJ* **369**, m1443 426 (2020).
- Taubenberger, J.K. & Morens, D.M. The pathology of influenza virus infections. *Annu Rev Pathol* **3**, 499-522 (2008).
- 429 8. Paules, C. & Subbarao, K. Influenza. *Lancet* **390**, 697-708 (2017).
- 430 9. Lessler, J., et al. Incubation periods of acute respiratory viral infections: a systematic review.
 431 Lancet Infect Dis **9**, 291-300 (2009).
- 432 10. Mehta, P., *et al.* COVID-19: consider cytokine storm syndromes and immunosuppression. 433 *Lancet* **395**, 1033-1034 (2020).
- 434 11. Wu, C., et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med* 436 (2020).
- 437 12. Yang, X., et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 438 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet* 439 *Respir Med* **8**, 475-481 (2020).
- 440 13. Galani, I.E., et al. Interferon-lambda Mediates Non-redundant Front-Line Antiviral Protection 441 against Influenza Virus Infection without Compromising Host Fitness. *Immunity* **46**, 875-890 442 e876 (2017).
- 14. Davidson, S., Crotta, S., McCabe, T.M. & Wack, A. Pathogenic potential of interferon alphabeta in acute influenza infection. *Nat Commun* **5**, 3864 (2014).
- 445 15. Andreakos, E., Zanoni, I. & Galani, I.E. Lambda interferons come to light: dual function 446 cytokines mediating antiviral immunity and damage control. *Curr Opin Immunol* **56**, 67-75 447 (2019).
- 448 16. Blanco-Melo, D., et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. *Cell* (2020).
- 450 17. Hadjadj, J., *et al.* Impaired type I interferon activity and inflammatory responses in severe 451 COVID-19 patients. *Science* **369**, 718-724 (2020).
- 452 18. WHO. Clinical management of severe acute respiratory infections when novel coronavirus is suspected: What to do and what not to do. (WHO, 2020).
- 454 19. Lim, W.S., *et al.* Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. *Thorax* **58**, 377-382 (2003).

- 456 20. Galani, I.E. & Andreakos, E. Neutrophils in viral infections: Current concepts and caveats. *J Leukoc Biol* **98**, 557-564 (2015).
- 458 21. Mangalmurti, N. & Hunter, C.A. Cytokine Storms: Understanding COVID-19. *Immunity* **53**, 19-459 25 (2020).
- 460 22. Chen, G., et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest* **130**, 2620-2629 (2020).
- 462 23. Liu, T., *et al.* The role of interleukin-6 in monitoring severe case of coronavirus disease 2019. 463 *EMBO Mol Med* (2020).
- Channappanavar, R., et al. Dysregulated Type I Interferon and Inflammatory Monocyte Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe
 19, 181-193 (2016).
- 467 25. Broggi, A., et al. Type III interferons disrupt the lung epithelial barrier upon viral recognition.
 468 Science **369**, 706-712 (2020).
- 469 26. Major, J., et al. Type I and III interferons disrupt lung epithelial repair during recovery from viral infection. *Science* **369**, 712-717 (2020).
- Wang, B.X. & Fish, E.N. The yin and yang of viruses and interferons. *Trends Immunol* **33**, 190-197 (2012).
- Wang, N., et al. Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is
 Associated with Favorable Clinical Responses in COVID-19 Patients. *Cell Host & Microbe*, 1-10
 (2020).
- Wathelet, M.G., Orr, M., Frieman, M.B. & Baric, R.S. Severe acute respiratory syndrome
 coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain.
 J Virol 81, 11620-11633 (2007).
- Kopecky-Bromberg, S.A., Martinez-Sobrido, L., Frieman, M., Baric, R.A. & Palese, P. Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. *J Virol* 81, 548-557 (2007).
- 482 31. Comar, C.E., et al. Antagonism of dsRNA-Induced Innate Immune Pathways by NS4a and NS4b Accessory Proteins during MERS Coronavirus Infection. *mBio* **10**(2019).
- 484 32. Liu, Y., et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis (2020).
- He, X., et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat Med* **26**, 672-675 (2020).
- 487 34. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7). *Chin* 488 *Med J (Engl)* **133**, 1087-1095 (2020).
- 489 35. Corman, V.M., et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. 490 Euro Surveill **25**(2020).
- 491 36. Love, M.I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* **15**, 550 (2014).

493




FIG. 1




FIG. 2




FIG. 3

